PHÂN TÍCH THỰC TRẠNG SỬ DỤNG TRASTUMAB TRÊN BỆNH NHÂN UNG THƯ VÚ ĐIỀU TRỊ TẠI BỆNH VIỆN UNG BƯỚU ĐÀ NẴNG

Abstract

Object: To analyze the characteristics of indications, routes of administration, usage and duration of treatment with trastuzumab in breast cancer (BC) patients. Subject and method: A retrospective descriptive study was conducted by reviewing medical records of BC patients prescribed trastuzumab at the Breast Oncology Department of Da Nang Oncology Hospital from 1/10/2023 to 30/9/2024. Result: Data were collected from 172 HER2-positive (HER2+) BC patients, encompassing a total of 2211 trastuzumab treatment cycles. At the initiation of trastuzumab therapy, 94,77% of patients were confirmed HER2+. The predominant concomitant chemotherapy regimen was an anthracycline-free, taxane-based protocol (87,2%). The proportion of patients receiving dual HER2 blockade therapy was 19,77%. Regarding the route of administration, 35,47% of patients experienced at least one change in administration route during their treatment course; 86,52% of trastuzumab cycles were administered subcutaneously. A 3-weekly trastuzumab regimen was utilized in 100% of patients; however, 0,83% of cycles had a duration of less than 18 days, and approximately 13% of cycles extended beyond 24 days, with the remainder ranging between 18 - 24 days. The median treatment duration was 12,13 months in the early-stage BC group and 30,03 months in the metastatic/recurrent BC group. Conclusion: The majority of patients received trastuzumab according to current guideline recommendations. However, patients who switched administration routes or received trastuzumab concurrently with anthracyclines warrant close monitoring for adverse events. Further research is necessary to investigate the reasons for shortened or prolonged treatment cycles and the absence of HER2 testing results at the initiation of trastuzumab therapy.